Abstract: Efficacy and Tolerability of a 12 week Course of Sofosbuvir-based
HCV Antiviral Therapy without Ribavirin for Treatment of Recurrent HCV Genotype 1 Infection after Liver Transplantation—M Hassett et. al
Source: The Liver Meeting – Late Breaker Abstract – LB 28
Results and Conclusions
The current study evaluated treating people post-transplant HCV. Forty-eight patients were treated with simeprevir plus sofosbuvir and 18 patients were treated with ledipasvir plus sofosbuvir. All patients were genotype 1. The length of treatment was 12 weeks.
The cure rates were 94% (45 of 48 pts) in the simeprevir plus sofosbuvir group and 100% (18 of 18 pts) in the ledipasvir plus sofosbuvir. The most common side effects were fatigue and headache. There were no treatment interruptions or treatment discontinuations due to side effects.
The Bottom Line
Both therapies produced very high cure rates with very few side effects. This is one of the most difficult treatment patient groups.
People who have recurrent hepatitis C infection after a liver transplant can face many potentially life-threatening problems. If you can cure hepatitis C as soon as possible after recovering from a transplant that will greatly improve long-term survival.
It is hard to believe that within in the last ten years HCV treatment has advanced this far. However, we now have those treatments and they are getting better all the time.
Labels: ledipasvir, Sofosbuvir, Treatment post-transplant